IDX184, the firm's lead product candidate for the treatment of hepatitis C virus (HCV) infection is a pan-genotypic oral nucleotide polymerase inhibitor, and has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.
Recently reported interim Phase IIb data showed favourable antiviral activity and no serious adverse events.
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
FDA accepts Genentech's giredestrant application for early-stage breast cancer
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Haisco receives US FDA approval for anaesthetic Cipepofol
Hanmi signs licensing deal with Lilly for sonefpeglutide
FDA approves TREMFYA label expansion
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)